文献速递骨质疏松与代谢性骨病

修饰RANKL-RANK结合位点用于骨质疏松免疫治疗

Modification of the RANKL-RANK-binding site for the immunotherapeutic treatment of osteoporosis.
PubMed 文献 · Osteoporos Int · 2019-12-20

本研究提出以点突变RANKL作为免疫原进行主动免疫,诱导抗细胞因子抗体治疗骨质疏松。基于RANKL-RANK复合物晶体结构设计突变体,免疫小鼠产生高滴度特异性抗体,体外阻断破骨细胞发育,并在RANKL处理或去卵巢小鼠模型中抑制骨质疏松。

要点

  • 突变RANKL免疫可诱导高滴度抗RANKL抗体
  • 该抗体体外阻断破骨细胞发育
  • 在RANKL处理或去卵巢小鼠中抑制骨质疏松

核心结论

  • 突变RANKL作为免疫原可成功诱导抗RANKL免疫应答,该策略可用于一般抗细胞因子免疫治疗以规避骨质疏松治疗的毒副作用。

研究设计与样本

  • 基于RANKL与其受体RANK复合物的晶体结构对RANKL进行点突变,作为概念验证研究。

主要发现

  • 用RANKL免疫产生高水平特异性抗体,体外阻断破骨细胞发育。
  • 在RANKL处理或去卵巢小鼠模型中抑制骨质疏松。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Here, we proposed the use of mutated RANKL as an immunogen for active immunization and to induce anti-cytokine antibodies for osteoporosis treatment. INTRODUCTION: Osteoclasts are responsible for bone resorption in bone-related disorders. Anti-cytokine therapeutic antibodies such as denosumab are effective for the treatment of osteoporosis. However, problems with antibody manufacturing and the immunogenicity caused by multiple antibody doses have led to the use of auto-cytokines as immunogens to induce anti-cytokine antibodies. METHODS: RANKL was point-mutated based on the crystal structure of the complex of RANKL and its receptor RANK. RESULTS: As a proof of concept, immunization with RANKL produced high levels of specific antibodies and blocked osteoclast development in vitro and inhibited osteoporosis in RANKL-treated or ovariectomized mouse models. CONCLUSIONS: The results demonstrate the successful use of mutated RANKL as an immunogen for the induction of anti-RANKL immune response. This strategy is useful in general anti-cytokine immunotherapy to avoid toxic side effects of osteoporosis treatment.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Ko Y, Lee G, Kim B, et al. Modification of the RANKL-RANK-binding site for the immunotherapeutic treatment of osteoporosis. Osteoporos Int. 2019. PMID: 31863125. doi:10.1007/s00198-019-05200-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。